Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors

El propósito de este estudio internacional es tratar de predecir qué pacientes son más propensos a desarrollar efectos adversos tras la radioterapia

News

REQUITE on Facebook

REQUITE Patient Leaflet!

In this Leaflet we would like to inform you on the progress of this project and to thank all the patients who agreed to take part in the REQUITE study. The Leaflet is available in English, Spanish, French, German, Italian and Dutch. 

Successful Radiogenomics Consortium Meeting and Final Requite Meeting in Manchester

The 11th annual RGC meeting was held at the Manchester Cancer Research Centre - Manchester’s newest cancer research facility on July 16th, 2018.  The Radiogenomics Consortium members presented the latest developments in the research on genetics of toxicity induced radiotherapy.
  • The first day of the Final REQUITE Symposium (17th July, 8:30-17:30, CityLabs) was open to REQUITE consortium me

Older news

Recruitment

Breast
2071
Lung
559
383*
Prostate
1809
* non-REQUITE patients included in our analyses

Events

ESMO2018 Congress: Securing access to optimal cancer care

ESMO is and continues to be a leading force of high-quality oncology education, a platform for immense international visibility for scientific research, and a proud contributor to continuous improvements in patient care.

For more information: website

Dates: 
Friday, 19 October, 2018 to Tuesday, 23 October, 2018
Location: 
Messe Munich
Messegelände
81823 München
Germany
DE

ASTRO 2018

ASTRO’S Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year.

Abstract Submission Site Opens: December 13, 2017
Abstract Submission Site Closes: February 14, 2018

Dates: 
Sunday, 21 October, 2018 to Wednesday, 24 October, 2018
Location: 
Henry B. Gonzalez Convention Center
900 E Market St
TX 78205 San Antonio
United States
US